Background

Leigh Hochberg is the scientific director of the BrainGate consortium, the most established clinical research network in brain-computer interfaces. He holds faculty positions at Brown University and Massachusetts General Hospital, where he maintains active clinical research programs in neural prosthetics.

BrainGate Foundation

Hochberg led the BrainGate2 clinical trial, which published the first peer-reviewed results demonstrating functional motor control via intracortical electrodes in paralyzed humans in 2006. This landmark publication established proof-of-concept for high-bandwidth BCIs and catalyzed subsequent commercial development by Neuralink, Blackrock, and other companies now pursuing similar methodologies.

Academic Leadership

As a professor at Brown University and senior lecturer at Harvard Medical School, Hochberg maintains influence over BCI research methodology, device design principles, and clinical trial conduct. His multi-institutional collaborative model at BrainGate includes partnerships with Stanford, Case Western Reserve, and Massachusetts General Hospital.

Continuing Innovation

Hochberg’s laboratory continues advancing speech neuroprosthetics, demonstrating real-time decoding of intended speech from paralyzed patients. His work bridges academic research and commercial development, establishing relationships with device manufacturers and regulatory agencies.

Research Philosophy

Hochberg emphasizes methodological rigor and long-term patient outcomes, contrasting with some commercial approaches focused on rapid advancement. His 20-year research trajectory demonstrates durability and safety considerations critical to clinical adoption.